1. Is Dr. Lal Pathlabs Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Dr. Lal Pathlabs Ltd is a good quality company.
2. Is Dr. Lal Pathlabs Ltd undervalued or overvalued?
The key valuation ratios of Dr. Lal Pathlabs Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
3. Is Dr. Lal Pathlabs Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Dr. Lal Pathlabs Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||37.4%||40.8%||34.4%||31.6%||28.8%||24.7%||22.7%||23.4%||26%||24.2%||-|
|Value Creation Index ⓘ||2.3||2.6||2.1||1.3||1.1||0.8||0.7||0.7||0.9||NA||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||28.4%||17.7%||20.2%||15.2%||16.1%||13.8%||9.3%||17%||25.6%||-|
|Adj EPS ⓘ||9.1||14||16.8||15.2||18.4||20.1||23.2||26.1||33.6||41.7||36|
|YoY Gr. Rt. %||-||52.6%||20.4%||-9.5%||21%||9.4%||15.1%||12.7%||28.8%||23.9%||-|
|BVPS (₹) ⓘ||28||35.2||53.6||57.9||69.6||91||108.3||118||141.3||170.3||179.8|
|Adj Net Profit ⓘ||49.1||74.9||91.8||126||153||168||193||218||280||347||300|
|Cash Flow from Ops. ⓘ||79.4||96.2||94.1||142||167||189||209||272||373||424||-|
|Debt/CF from Ops. ⓘ||0||0||0||0||0||0||0||0||0||0.8||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||18.4%||17.8%||21.6%||23.9%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||37.2||40.7||34.3||31.5||28.7||24.6||22.6||22.3||25.1||25.8||20.6|
|Op. Profit Mgn % ⓘ||20.6||25.1||23.6||26.4||26.1||25||24.3||25.7||27.3||27.5||25.6|
|Net Profit Mgn % ⓘ||11.7||13.9||14.4||16.4||17.3||16.4||16.6||17.1||18.8||18.5||17.2|
|Debt to Equity ⓘ||0||0||0||0||0||0||0||0||0||0.2||-|
|Working Cap Days ⓘ||42||43||53||66||66||66||62||52||45||36||0|
|Cash Conv. Cycle ⓘ||-19||-17||-14||-15||-10||-12||-13||-15||-21||-19||0|
Sales growth is growing at healthy rate in last 3 years 17.15%
Net Profit is growing at healthy rate in last 3 years 21.63%
Return on Equity has declined versus last 3 years average to 20.60%
Sales growth is not so good in last 4 quarters at -1.07%
|TTM EPS (₹)||36||32.6|
|TTM Sales (₹ Cr.)||1,747||1,984|
|BVPS (₹.) ⓘ||179.8||180.9|
|Reserves (₹ Cr.) ⓘ||1,415||1,425|
|From the Market|
|52 Week Low / High (₹)||1805.10 / 4243.00|
|All Time Low / High (₹)||696.50 / 4243.00|
|Market Cap (₹ Cr.)||20,285|
|Equity (₹ Cr.)||83.4|
|Face Value (₹)||10|
|Industry PE ⓘ||60.6|
The company was incorporated as ‘Dr. Lal PathLabs Private Limited’, a private limited company under the Companies Act, 1956, with a certificate of incorporation issued by the Registrar of Companies, National Capital Territory of Delhi and Haryana (RoC) on February 14, 1995 at Delhi. Subsequently, the name of the company was changed to ‘Dr. Lal PathLabs Limited’ upon conversion of the company into a public limited company pursuant to a special resolution of the shareholders of the company dated August 7, 2015 and a fresh certificate of incorporation was issued by the RoC on August 19, 2015. There has been no change in the registered office of the company since incorporation of the company.
The company focuses on providing patients quality diagnostic and related healthcare tests and services. The company’s focus on the patient as a customer is a critical differentiator in the diagnostic and healthcare industries and, together with what its brand’s recognition for quality diagnostic services, results in individuals and healthcare providers choosing it as their diagnostic healthcare service provider. This is because (i) in India, patients generally choose their diagnostic healthcare service provider and (ii) patients and healthcare providers seek quality healthcare service providers due to what range in quality and reliability of diagnostic healthcare services in India.
With over 3,368 diagnostic and related healthcare tests and services offered, the company is capable of performing substantially all of the diagnostic healthcare tests and services currently prescribed by physicians in India. Its diagnostic and related healthcare tests and services include (i) routine clinical laboratory tests - such as blood chemistry analyses and blood cell counts; (ii) specialized testing services - such as histopathology analyses, genetic marker-based tests, viral and bacterial cultures and infectious disease tests; and (iii) preventive testing services - such as screenings for hypertension, heart disease and diabetes. It performs these tests and services in its clinical laboratories using sophisticated and computerized instruments.
The company has built a national, “hub and spoke” network that includes its National Reference Laboratory in New Delhi. The company’s “hub and spoke” model, whereby specimens are collected across multiple locations within a region for delivery to a predesignated clinical laboratory for centralized diagnostic testing, provides greater economies of scale and offers a scalable platform for the continued growth of its business. Its network is present across India, including large cities such as New Delhi, Mumbai, Bengaluru, Chennai, Hyderabad and Kolkata. The company’s centralized information technology platform fully integrates its large network through a common logistics and payments system and tracks its operations and internal performance metrics, thereby enabling it to improve the efficiencies of its business.
Business area of the company
The company is a provider of diagnostic and related healthcare tests and services in India. Through its integrated, nationwide network, the company offers patients and healthcare providers a broad range of diagnostic and related healthcare tests and services for use in core testing, patient diagnosis and the prevention, monitoring and treatment of disease and other health conditions. Its customers include individual patients, hospitals and other healthcare providers and corporate customers.
Awards and accreditations
Major events and milestones